METHOD FOR PREDICTION OF LIFE EXPECTANCY IN PATIENTS WITH METASTATIC TUMORS Russian patent published in 2024 - IPC G01N33/52 C12Q1/6886 G16H50/30 

FIELD: medicine; oncology.

SUBSTANCE: invention can be used for prediction of life expectancy of patients with metastatic forms of tumors. Absolute concentration of cells with phenotypes is evaluated in the tumor microenvironment once and in the blood lymphocyte culture twice with an interval of at least one week. CD3+CD16−, CD3+CD8+, CD3−CD16+CD56+, CD3+CD16+CD56+, CD4+CD25+CD127−FOXP3, LIN−HLADR−CD33+CD66b−CD14+CD15−, CD4+CD8+ and spontaneous production of cytokines IFN-γ, IL-4, IL-8, IL-12, TNF-α. Obtained values are used to calculate the coefficients K1 and K2. Further, values of functions F1= and F2=. If K1 ≥ 0, K2 < 0, F1 ≥ 1.55 at any value of F2, then the predicted life expectancy is more than 22 months. If K1 ≥ 0, K2 < 0, F1 < 1.55 at any value of F2 or K1 ≥ 0, K2 ≥ 0 and F2 ≥ 1 at any value of F1, then the predicted life expectancy is not less than 16, but not more than 22 months. If K1 ≥ 0, K2 ≥ 0, F2 < 1 at any value of F1, or K1 < 0, K2 ≥ 0 and F1 < 1.81 at any value of F2, or K1 < 0, K2 < 0 and F2 ≥ 1 at any value F1, then the predicted life expectancy is not less than 8, but not more than 16 months. If K1 < 0, K2 ≥ 0, F1 ≥ 1.81 at any value of F2 or K1 < 0, K2 < 0 and F2 < 1 at any value of F1, then the predicted life expectancy is less than 8 months.

EFFECT: method enables predicting life expectancy in the patients with disseminated tumors by analyzing the parameters affecting the median overall survival rate.

1 cl, 11 tbl